DOCSLIB.ORG

Tropisetron(BAN, Rinn)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tropisetron(BAN, Rinn) Tamarind/Tropisetron 1777 Profile Tropisetron (BAN, rINN) tensive metabolisers and up to 45 hours in poor metab- Tiemonium iodide and tiemonium metilsulfate are quaternary olisers. Clearance is also reduced in patients with renal ammonium antimuscarinics with peripheral effects similar to Tropisétron; Tropisetrón; Tropisetroni; Tropisetronum. impairment. those of atropine (p.1219) and are used in the relief of visceral 1αH,5αH-Tropan-3α-yl indole-3-carboxylate. spasms. Трописетрон Tiemonium metilsulfate is given in an oral dose of 100 to 300 mg Uses and Administration C H N O = 284.4. daily in divided doses. A dose of 5 mg has been given three times 17 20 2 2 Tropisetron is a 5-HT3 antagonist with an antiemetic daily by intramuscular or slow intravenous injection. Tiemonium CAS — 89565-68-4. action similar to that of ondansetron (p.1757). It is used metilsulfate has also been given as a rectal suppository in daily ATC — A04AA03. in the prevention of nausea and vomiting induced by doses of 20 to 40 mg. ATC Vet — QA04AA03. cytotoxic therapy and in the treatment and prevention Tiemonium iodide has been used similarly. of postoperative nausea and vomiting (p.1700). Preparations CH Tropisetron is given as the hydrochloride by slow intra- Proprietary Preparations (details are given in Part 3) 3 venous injection or infusion, or orally. Doses are ex- Belg.: Visceralgine†; Fr.: Visceralgine; Indon.: Visceralgine. N pressed in terms of tropisetron base; 5.64 mg of tropi- Multi-ingredient: Belg.: Asodal; Fr.: Colchimax; Visceralgine Forte†; Venez.: Bort†. setron hydrochloride is equivalent to about 5 mg of tropisetron base. H N For the prophylaxis of acute nausea and vomiting as- Timepidium Bromide (rINN) sociated with cytotoxic chemotherapy a single dose of Bromuro de timepidio; SA-504; Timepidii Bromidum; Timépid- O 5 mg may be given by slow intravenous injection or ium, Bromure de. 3-[Di-(2-thienyl)methylene]-5-methoxy-1,1- infusion on the day of treatment, shortly before chemo- dimethylpiperidinium bromide monohydrate. O therapy. The injection is given over not less than 1 Тимепидия Бромид minute; it may be given into a running infusion. For infusion, it is diluted into 100 mL of a suitable infusion C17H22BrNOS2,H2O = 418.4. CAS — 35035-05-3. Tropisetron Hydrochloride (BANM, rINNM) fluid (such as sodium chloride 0.9% or glucose 5%), ATC — A03AB19. Hidrocloruro de tropisetrón; ICS-205-930; Tropisétron, chlorhy- and given over 15 minutes. Subsequent doses of 5 mg ATC Vet — QA03AB19. drate de; Tropisetroni hydrochloridum. daily are given orally, in the morning at least one hour Трописетрона Гидрохлорид before food, for a further 5 days. C17H20N2O2,HCl = 320.8. Children over 2 years of age may be given CAS — 105826-92-4. 200 micrograms/kg (maximum dose 5 mg) before CH3 ATC — A04AA03. chemotherapy, by intravenous injection over at least 1 H3C N+ S ATC Vet — QA04AA03. minute, or by infusion (at a concentration of Br- Pharmacopoeias. In Eur. (see p.vii). 50 micrograms/mL in a suitable infusion fluid). In chil- Ph. Eur. 6.2 (Tropisetron Hydrochloride). A white or almost dren weighing less than 25 kg the same dose may be white powder. Freely soluble or soluble in water; sparingly solu- given intravenously once daily for up to a further 4 3C OH S ble in alcohol; very slightly soluble in dichloromethane. days as required. In those weighing more than 25 kg, a dose of 5 mg may be given orally once daily for up to Adverse Effects and Precautions a further 5 days; if oral dosage is not possible the same Pharmacopoeias. In Jpn. As for Ondansetron, p.1757. Fatigue, abdominal pain, dose may be given intravenously. and diarrhoea may also occur. Visual hallucinations, Profile and an increase in blood pressure in patients with pre- For the treatment of postoperative nausea and vomit- Timepidium bromide is a quaternary ammonium antimuscarinic ing in adults 2 mg may be given by slow intravenous with peripheral actions similar to those of atropine (p.1219). It existing hypertension, have been noted at high repeat- has been given for the symptomatic treatment of visceral spasms ed doses. ECG changes such as prolongation of QT in- injection (over not less than 30 seconds), or by infusion in usual oral doses of 30 mg three times daily. It has also been terval have been noted with high-dose intravenous tro- (over 15 minutes), within 2 hours of the end of anaes- given by subcutaneous, intramuscular, and intravenous injection pisetron. The drug should therefore be used with thesia. For prophylaxis, the same dose may be given in a dose of 7.5 mg. caution in patients with cardiac rhythm or conduction shortly before induction of anaesthesia. Urinary metabolites of timepidium may cause a reddish colora- tion of the urine. disturbances. Care should be taken when driving or op- ◊ References. erating machinery. No dosage reduction is considered 1. Lee CR, et al. Tropisetron: a review of its pharmacodynamic and Preparations necessary in renal or hepatic impairment despite possi- pharmacokinetic properties, and therapeutic potential as an an- tiemetic. Drugs 1993; 46: 925–43. Proprietary Preparations (details are given in Part 3) ble reductions in clearance. 2. Simpson K, et al. Tropisetron: an update of its use in the preven- Indon.: Sesden; Jpn: Sesden; Singapore: Sesden†. tion of chemotherapy-induced nausea and vomiting. Drugs Carcinogenicity. The manufacturer (Novartis, UK) has report- 2000; 59: 1297–1315. ed an increased incidence of hepatic neoplasms in male mice giv- en high doses of tropisetron but it is suggested that these effects Anxiety disorders. A dose-dependent anxiolytic effect was re- Tridihexethyl Chloride (BAN, rINNM) are both species and sex specific. ported for tropisetron when studied in patients with generalised 1 anxiety, but clinical evidence for the benefit of 5-HT3 antago- Cloruro de tridihexetilo; Tridihexéthyl, Chlorure de; Tridihexe- Effects on the cardiovascular system. For a discussion of nists in anxiety disorders is lacking.2 thyli Chloridum. (3-Cyclohexyl-3-hydroxy-3-phenylpropyl)tri- the effects of 5-HT antagonists on the cardiovascular system, 3 1. Lecrubier Y, et al. A randomized double-blind placebo-control- ethylammonium chloride. see under Ondansetron, p.1757. led study of tropisetron in the treatment of outpatients with gen- Тридигексетила Хлорид eralized anxiety disorder. Psychopharmacology (Berl) 1993; Interactions 112: 129–33. C21H36ClNO = 354.0. 2. Greenshaw AJ, Silverstone PH. The non-antiemetic uses of sero- CAS — 60-49-1 (tridihexethyl); 4310-35-4 (tridihexethyl Drugs that induce or inhibit hepatic enzymes may af- tonin 5-HT receptor antagonists: clinical pharmacology and chloride); 125-99-5 (tridihexethyl iodide). fect plasma concentrations of tropisetron. Licensed therapeutic applications. Drugs 1997; 53: 20–39. ATC — A03AB08. product information considers that any changes are Fatigue. Tropisetron has been reported to be of benefit in pa- ATC Vet — QA03AB08. usually unlikely to be clinically relevant with the rec- tients with chronic fatigue, see under Uses and Administration of ommended doses. Ondansetron, p.1758. Pain. For reference to the use of tropisetron in various painful CH Tropisetron should be used with caution with anti- 3 arrhythmics, beta blockers, or drugs likely to prolong syndromes, see under Uses and Administration of Ondansetron, p.1758. HO + the QT interval, including those likely to cause electro- N CH3 − lyte disturbances (see also p.1757). Pruritus. Tropisetron and other 5-HT3 antagonists have been Cl investigated for the management of pruritus (see under On- dansetron, p.1758). CH3 Pharmacokinetics Tropisetron is well absorbed after oral doses. Peak Preparations plasma concentrations are achieved within 3 hours. Proprietary Preparations (details are given in Part 3) Absolute bioavailability depends on the dose since Arg.: Navoban; Austral.: Navoban; Austria: Navoban; Belg.: Novaban; Braz.: Navoban†; Chile: Navoban; Cz.: Navoban†; Denm.: Navoban; NOTE. Tridihexethyl Iodide is rINN. first-pass metabolism is saturable. It is 71% bound to Fin.: Navoban; Fr.: Navoban; Ger.: Navoban; Gr.: Navoban; Hong Kong: plasma proteins. Tropisetron is metabolised by hydrox- Navoban; Hung.: Navoban; Indon.: Navoban; Setrovel; Israel: Navoban†; Profile Ital.: Navoban; Jpn: Navoban; Malaysia: Navoban; Mex.: Navoban; Tridihexethyl chloride is a quaternary ammonium antimuscarin- ylation and conjugation, and metabolites are excreted Neth.: Novaban; Norw.: Navoban; NZ: Navoban; Philipp.: Navoban; ic with peripheral effects similar to those of atropine (p.1219). It mainly in the urine with a small amount in the faeces. Pol.: Navoban; Port.: Navoban; Rus.: Navoban (Навобан); Tropindol (Тропиндол)†; S.Afr.: Navoban; Spain: Navoban; Saronil; Swed.: Na- has been used as an adjunct in the treatment of peptic ulcer dis- The cytochrome P450 isoenzyme CYP2D6 is involved voban; Switz.: Navoban; Thai.: Navoban; Turk.: Navoban; UK: Navoban; ease. in tropisetron metabolism, and shows genetic polymor- Venez.: Navoban. phism. The elimination half-life is about 8 hours in ex- The symbol † denotes a preparation no longer actively marketed The symbol ⊗ denotes a substance whose use may be restricted in certain sports (see p.vii).
Load more

Recommended publications
  • United States Patent Office
    3,092,548 United States Patent Office Patented June 4, 1963 2 are the various side effects that occur in an appreciable 3,092,548 number of patients, the foremost of which are a blurring METHOD OF TREATING PEPTICULCERS WITH PANTOTHENECACD of vision, drowsiness and a general dry condition mani Albert G. Worton, Columbus, Ohio, assignor to The fested by a retarded salivation, reduction of perspiration Warren-Teed Products Company, Columbus, Ohio, a 5 and diminished urinary output. Other side effects which corporation of Ohio occur in some cases are glaucoma, stimulation of the cen No Drawing. Filed Oct. 27, 1960, Ser. No. 65,256 trol nervous system and in severe cases cardiac and respi 5 Claims. (Ci. 67-55) ratory collapse. These side effects increase to Some de gree with the increase in dosage. Despite the side effects This invention relates to preparation adapted for use O these compounds are fairly selective and highly effective in treating disorders of the gastro-intestinal tract, more in decreasing the volume and acidity of gastric secretion particularly in treating peptic ulcer, both of the duodenal and in reducing gastrointestinal motility. and gastric type, for hyperacidity, hypertropic gastritis, Understandably, the main problem in the past has been splenic flexure syndrome, biliary dyskinesia (postchole to provide a dosage of anticholinergic drug which will cystectomy syndrome) and hiatal hernia or other condi achieve the most beneficial results possible and yet mini tions where anticholinergic effect, either spasmolytic or mize the undesired side effects. One of the objects of antisecretory is indicated or where antiuicerogenic effect this invention is to provide novel compositions containing is indicated.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • United States Patent (19) 11 4,111,203 Theeuwes (45) "Sep
    United States Patent (19) 11 4,111,203 Theeuwes (45) "Sep. 5, 1978 54) OSMOTIC SYSTEM WITH MEANS FOR Primary Examiner-Benjamin R. Padgett MPROVING DELVERY KNETCS OF Assistant Examiner-T. S. Gron SYSTEM Attorney, Agent, or Firm-Paul L. Sabatine; Thomas E. 75 Inventor: Felix Theeuwes, Los Altos, Calif. Ciotti; Edward L. Mandell 73) Assignee: Alza Corporation, Palo Alto, Calif. 57 ABSTRACT * Notice: The portion of the term of this patent An osmotic system for delivering a beneficial agent is subsequent to Sep. 5, 1995, has been disclosed. The system comprises a wall surrounding a disclaimed. compartment and has a passageway through the wall for delivering agent from the compartment. The wall is (21) Appl. No.: 744,089 formed of a material permeable to the passage of an (22 Filed: Nov. 22, 1976 external fluid and impermeable to the passage of agent. 51) Int. Cl’............................................. A61M31/00 The compartment contains an agent that is soluble in 52 U.S. C. ..................................... 128/260; 206/0.5; the fluid and exhibits an osmotic pressure gradient 222/130; 222/193; 222/389; 222/395; 222/491; across the wall against the fluid, or the compartment 424/19 contains an agent that has limited solubility in the fluid 58) Field of Search ............... 128/260, 261,268, 272; and exhibits a limited osmotic pressure gradient across 424/15, 19-22, 33, 37; 222/491,395, 193,389, the wall against the fluid. The compartment also con 130; 206/0.5 tains means for increasing the amount of agent deliv ered from the system. The means comprises a film sur (56) References Cited rounding an osmagent with the film formed of a mate U.S.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]